NDAORALTABLET
Approved
Apr 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
BENICAR (olmesartan medoxomil) by Jubilant Therapeutics is (ace, kininase ii). Approved for hypertension, diabetic nephropathy. First approved in 2002.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BENICAR (olmesartan medoxomil) is an oral angiotensin II receptor blocker (ARB) approved in 2002 for treatment of hypertension in adults and elderly patients, either as monotherapy or in combination with other antihypertensive agents. It works by selectively blocking angiotensin II binding to AT1 receptors in vascular smooth muscle, thereby reducing vasoconstriction and blood pressure. Unlike ACE inhibitors, olmesartan does not inhibit bradykinin degradation, which may have clinical implications for tolerability. The drug is indicated for hypertension management and has been studied in heart failure populations.
$0.0BPart D
Mechanism of Action
(ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation and renal reabsorption of sodium. Olmesartan blocks the vasoconstrictor effects of…
Indications (2)
Worked on BENICAR at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.